La traduzione di questa pagina è sperimentale e in fase di sviluppo. Siamo lieti di ricevere vostro !
Clovis Oncology Performance dei guadagni passati
Il passato criteri di controllo 0/6
Clovis Oncology has been growing earnings at an average annual rate of 5.6%, while the Biotechs industry saw earnings growing at 32.7% annually. Revenues have been growing at an average rate of 16.8% per year.
Informazioni chiave
5.6%
Tasso di crescita degli utili
24.5%
Tasso di crescita dell'EPS
| Biotechs Crescita del settore | 17.0% |
| Tasso di crescita dei ricavi | 16.8% |
| Rendimento del capitale proprio | n/a |
| Margine netto | -189.4% |
| Ultimo aggiornamento sui guadagni | 30 Sep 2022 |
Aggiornamenti sulle prestazioni recenti
Recent updates
Clovis Oncology rises on clinical supply agreement with Isotopia
Sep 21Clovis stock rises 15% as Rubraca shows survival benefit as maintenance therapy for ovarian cancer in trial
Sep 12Clovis Oncology: Needs Some Encouraging Data Quickly
Aug 11These Analysts Think Clovis Oncology, Inc.'s (NASDAQ:CLVS) Sales Are Under Threat
Aug 10
Clovis Oncology Q2 2022 Earnings Preview
Aug 05EMA recommends restricted use of Clovis cancer drug
Jul 22Clovis Oncology climbs 34% as shareholders reject reverse stock split
Jul 08Clovis: Shifting Toward Nuclear Medicine
Apr 25Clovis Oncology: Forging A Fresh Perspective
Mar 31News Flash: 4 Analysts Think Clovis Oncology, Inc. (NASDAQ:CLVS) Earnings Are Under Threat
Feb 24Buying Beaten Down Clovis Oncology Stock Ahead Of 2022 Catalysts
Jan 11Clovis Oncology Is Now Discounted And Offers A Great Risk-Reward
Dec 30Clovis Oncology Stock: Only Glimmers Of Hope
Oct 07Clovis: Compelling With Upcoming Catalysts
Jul 30Here's Why Shareholders May Want To Be Cautious With Increasing Clovis Oncology, Inc.'s (NASDAQ:CLVS) CEO Pay Packet
Jun 17Clovis Oncology and Inovio gain amid Reddit chatter
Jun 09Clovis Oncology: Another Upcycle Coming
May 08Clovis Oncology drops 7% as Rubraca sales missed estimates amid continued COVID-19 headwinds
May 05Don't Ignore The Fact That This Insider Just Sold Some Shares In Clovis Oncology, Inc. (NASDAQ:CLVS)
Mar 17How Much Did Clovis Oncology's(NASDAQ:CLVS) Shareholders Earn From Share Price Movements Over The Last Three Years?
Feb 22Clovis Oncology: Recent Rally Already Has Me Changing My Game Plan
Jan 31Clovis Oncology: Finally Green Shoots May Be On The Horizon
Jan 29Clovis Oncology reports preliminary Q4 Rubraca revenue between $43.0M to $43.5M
Jan 11What Kind Of Investors Own Most Of Clovis Oncology, Inc. (NASDAQ:CLVS)?
Dec 31
Clovis Oncology submits FAP-2286 applications for therapeutic and imaging clinical trial
Dec 29Clovis stock rises as rubraca shows survival benefit in late-stage ovarian cancer study
Dec 21Clovis Oncology existing holder purchases additional $7.5M convertible senior notes
Nov 25Clovis Oncology: Cash Position Is Tight, We Question Management's Guidance
Nov 09Clovis Oncology: Reloading Before And After Q3 Earnings For The Long Term
Nov 06Clovis Oncology EPS beats by $0.11, misses on revenue
Nov 05Ripartizione dei ricavi e delle spese
Come Clovis Oncology guadagna e spende denaro. In base agli ultimi utili dichiarati, su base LTM.
Storia dei guadagni e delle entrate
| Data | Ricavi | Guadagni | Spese G+A | Spese di R&S |
|---|---|---|---|---|
| 30 Sep 22 | 133 | -252 | 126 | 151 |
| 30 Jun 22 | 140 | -263 | 127 | 167 |
| 31 Mar 22 | 145 | -258 | 128 | 176 |
| 31 Dec 21 | 149 | -265 | 128 | 187 |
| 30 Sep 21 | 156 | -299 | 136 | 201 |
| 30 Jun 21 | 157 | -310 | 142 | 218 |
| 31 Mar 21 | 160 | -336 | 151 | 242 |
| 31 Dec 20 | 165 | -369 | 164 | 258 |
| 30 Sep 20 | 161 | -370 | 168 | 273 |
| 30 Jun 20 | 159 | -385 | 171 | 288 |
| 31 Mar 20 | 152 | -413 | 178 | 289 |
| 31 Dec 19 | 143 | -400 | 183 | 283 |
| 30 Sep 19 | 134 | -400 | 187 | 282 |
| 30 Jun 19 | 119 | -396 | 187 | 268 |
| 31 Mar 19 | 110 | -377 | 184 | 250 |
| 31 Dec 18 | 95 | -368 | 176 | 231 |
| 30 Sep 18 | 82 | -321 | 165 | 198 |
| 30 Jun 18 | 76 | -291 | 158 | 173 |
| 31 Mar 18 | 67 | -366 | 149 | 154 |
| 31 Dec 17 | 56 | -346 | 139 | 142 |
| 30 Sep 17 | 39 | -365 | 113 | 159 |
| 30 Jun 17 | 22 | -370 | 87 | 174 |
| 31 Mar 17 | 7 | -324 | 60 | 209 |
| 31 Dec 16 | 0 | -349 | 41 | 251 |
| 30 Sep 16 | 0 | -398 | 37 | 273 |
| 30 Jun 16 | 0 | -431 | 36 | 294 |
| 31 Mar 16 | 0 | -373 | 34 | 287 |
| 31 Dec 15 | 0 | -353 | 31 | 269 |
| 30 Sep 15 | 0 | -288 | 28 | 243 |
| 30 Jun 15 | 0 | -229 | 25 | 202 |
| 31 Mar 15 | 0 | -192 | 23 | 170 |
| 31 Dec 14 | 14 | -160 | 21 | 138 |
| 30 Sep 14 | 14 | -134 | 19 | 110 |
| 30 Jun 14 | 14 | -115 | 18 | 91 |
| 31 Mar 14 | 14 | -100 | 16 | 79 |
| 31 Dec 13 | 0 | -85 | 17 | 67 |
| 30 Sep 13 | 0 | -76 | 14 | 61 |
| 30 Jun 13 | 0 | -74 | 12 | 60 |
| 31 Mar 13 | 0 | -71 | 11 | 57 |
| 31 Dec 12 | 0 | -74 | 11 | 58 |
Guadagni di qualità: CLVS.Q is currently unprofitable.
Margine di profitto in crescita: CLVS.Q is currently unprofitable.
Flusso di cassa libero e analisi degli utili
Analisi della crescita degli utili nel passato
Andamento degli utili: CLVS.Q is unprofitable, but has reduced losses over the past 5 years at a rate of 5.6% per year.
Accelerare la crescita: Unable to compare CLVS.Q's earnings growth over the past year to its 5-year average as it is currently unprofitable
Guadagni vs Settore: CLVS.Q is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (-43.2%).
Rendimento del capitale proprio
ROE elevato: CLVS.Q's liabilities exceed its assets, so it is difficult to calculate its Return on Equity.